<DOC>
	<DOCNO>NCT01792830</DOCNO>
	<brief_summary>Most coronary artery bypass graft surgery ( CABG ) patient develop high blood sugar hospital . No study show best insulin regimen CABG patient type 2 diabetes go home hospital . Patients high blood sugar diabetes cardiac bypass surgery follow 3 month look well treatment ( ) diabetes work discharge . Patients diabetes discharged oral antidiabetic drug insulin glargine injection base sugar control . Patients admission HbA1c &lt; 7 % ( laboratory value show average blood sugar level body 3 month ) discharge diabetes medication use come hospital . Those HbA1c 7 % 9 % discharged insulin glargine 50 % -80 % dose use hospital oral antidiabetic drug . Those HbA1c &gt; 9 % discharged glargine 80-100 % dose use hospital addition oral antidiabetic drug insulin glargine insulin glulisine . The primary outcome change HbA1c 4 12 week discharge .</brief_summary>
	<brief_title>Efficacy Safety Glargine-based Hospital Discharge Algorithm Coronary Artery Bypass Graft ( CABG ) Patients</brief_title>
	<detailed_description>Hospital discharge represent critical time ensure safe transition outpatient set reduce need emergency department visit re-hospitalization . Poor coordination patient care education insulin administration time patient discharge home may associate medical error may increase risk hypoglycemia , hyperglycemia hospital readmission . No prospective study examine impact discharge treatment regimen cardiac surgery . Therefore , study aim determine efficacy safety HbA1c base treatment algorithm control blood glucose ( BG ) discharge . The total duration study 3 month . This study include diabetic non-diabetic subject participate American Diabetes Association ( ADA ) trial entitle `` Intensive Insulin Therapy Patients Undergoing Coronary Artery Bypass Surgery . '' The ADA study two-arm randomized multicenter , open-label control trial aim determine intensive insulin control BG target 100-140mg/dl reduce perioperative complication compare conventional BG control target 141-180 mg/dl hyperglycemic subject undergo coronary artery bypass graft surgery ( CABG ) . Treatment recommendation discharge : - Patients admission HbA1c &lt; 7 % : - Patients without history diabetes require subcutaneous ( SC ) insulin hospital discharge antidiabetic therapy . - Patients without history diabetes require SC insulin therapy hospital discharge metformin monotherapy . A patient without history diabetes require SC insulin likely newly diagnose diabetic . The HbA1c value important confirm diagnosis . If HbA1c &gt; 6.5 % , he/she diagnose diabetes . We anticipate patient without history diabetes HbA1c &lt; 6.5 % require insulin treatment oral agent long-term . Those patient discharge anti diabetic therapy repeat test discharge rule diabetes . - Patients history diabetes discharge outpatient antidiabetic regimen ( diet , oral antidiabetic agent and/or insulin ) . - Assure contraindication oral agent ( i.e.Thiazolidinediones ( TZDs ) heart failure ; metformin renal failure heart failure ) . - Patients Admission HbA1c 7 % 9 % : - Treatment naïve patient pharmacologic treatment prior admission discharge metformin monotherapy combination metformin single dose basal ( glargine ) insulin 50 % total daily hospital dose . - Patients treated oral antidiabetic agent glucagon-like peptide-1 ( GLP1 ) analogs prior admission discharge pre-admission oral antidiabetic therapy plus single dose glargine insulin 50 % total daily hospital dose . - Patients treated combination oral antidiabetic agent basal insulin ( NPH insulin also know Neutral Protamine Hagedorn insulin , glargine , detemir ) prior admission discharge pre-admission oral antidiabetic therapy plus single dose glargine insulin basal bolus insulin regimen 50 % total daily hospital dose . - Patients treated oral agent discharge glargine monotherapy basal bolus 100 % inpatient total daily dose . - Admission HbA1c ≥ 9 % prior admission : - Discharge basal bolus regimen inpatient total daily insulin dose . - Basal insulin ( glargine ) daily , time day . - Rapid-acting insulin ( glulisine ) meal . - Alternative treatment : If contraindication oral agent ( i.e. , Thiazolidinediones ( TZDs ) heart failure ; metformin renal failure ) restart oral agent combination glargine daily 80 % total daily hospital dose .</detailed_description>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Males female age 18 80 year undergoing primary coronary artery bypass graft surgery ( CABG ) . 2 . Post surgical hyperglycemia ( Blood glucose &gt; 140 mg/dl ) 3 . Patients without history type 2 diabetes 1 . Patients severely impaired renal function ( serum creatinine ≥3.0 mg/dl glomerular filtration rate &lt; 30 ml/min ) clinically significant hepatic failure . 2 . Subjects acute hyperglycemic crisis diabetic ketoacidosis ( DKA ) hyperosmolar hyperglycemic state . 3 . Moribund patient imminent risk death ( brain death cardiac standstill ) . 4 . Patients nexttokin mental condition render subject family member unable understand nature , scope , possible consequence study . 5 . Female subject pregnant breastfeeding time enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Coronary Artery Bypass Graft surgery</keyword>
</DOC>